Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis

Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues

(2010) Vlad Ratziu et al.   HEPATOLOGY

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice

(2009) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

(2008) C. Fernández-Miranda et al.   DIGESTIVE AND LIVER DISEASE

Animal models of NASH: Getting both pathology and metabolic context right

(2008) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY